ICU
SeaStar Medical Holding Corp
NASDAQ · Healthcare · Biotechnology · US
$3.54
+1.22%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$3.51
From 52W high−71.45%
Volume77702.00
Market cap$15.60M
P/E (TTM)—
P/S (TTM)9.1x
Div yield—
Key dataSep 18, 2026
Open
$3.51
From 52W high
−71.45%
Volume
77702.00
Market cap
$15.60M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.6x
P/E (TTM)
—
RSI (14)
63.3
MomentumView details →
1D Return
+1.22%
YTD Return
+48.96%
SummaryUpdated Jun 1, 2026
SeaStar Medical Holding Corporation (NASDAQ:ICU) is a Denver-based medical device company that went public in March 2021. The company specializes in developing extracorporeal therapies designed to treat hyperinflammation and cytokine storm in critically ill patients. SeaStar focuses on targeting the cellular mechanisms that drive systemic inflammation, which can cause direct tissue damage and trigger cascading immune responses that worsen patient outcomes in intensive care settings.
Similar companies
Latest newsMore news →
SeaStar Medical Holding Corporation expanded adoption of its QUELIMMUNE product to 20 of 50 premier children's hospitals, targeting 25 by year-end.38d agoSeaStar Medical reported its second quarter 2026 financial results, with net revenue up 82% versus the second quarter of 2025, and added three top-rated children's hospitals to its QUELIMMUNE pediatric acute kidney injury customer base.38d ago